- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01080040
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity and the quality of life (QoL).
The purpose of this observational study is to assess the incidence of spasticity in a group of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina and the way it affects the QoL of these subjects.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
One of most frequently observed symptoms in subjects with MS is spasticity. Spasticity is defined as an abnormal velocity-dependent increase in muscle tonic stretch reflexes due to an amplified reactivity of motor segments to sensory input. It is part of one of the components of the superior motoneurone syndrome and it may cause muscle rigidity and disability.
The spasticity, which could be measured in electrophysiological, biomechanical and clinical terms, has a significant prevalence. It is a frequent cause for consultation among subjects with MS and, consequently, has a significant impact on the QoL. Men and those subjects with MS of longer duration are the most affected by spasticity.
The aim of this study is to assess the impact that spasticity has on the QoL of subjects with MS.
The total duration of the study is 24 months. The recruiting period will be 12 months. Once the recruiting time is over, the collection of data will continue during the full 24 months period that was planned.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Rosario, Argentina
- Fundacion Rosarina de Neurorehabilitacion
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Subjects aged from 21 60 years of age
- Subjects with established diagnosis of RRMS according to the revised McDonald criteria - 2005
- Subjects with a diagnosis of RRMS for more than one year
- The subject who have signed the Informed Consent
Exclusion Criteria:
- Subjects with other causes of spasticity
- Subjects with other clinical forms of MS (different from relapsing-remitting)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess the prevalence of spasticity in subjects with RRMS
Tidsramme: Initial visit (Day 0) to 24 months
|
Ashworth Scale (AS) (Spasticity) Expanded Disability status scale (EDSS) SF 36
|
Initial visit (Day 0) to 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Evaluation of the impact of spasticity on the quality of life of subjects with RRMS
Tidsramme: Initial visit (Day 0) to 24 months
|
Initial visit (Day 0) to 24 months
|
|
Evaluation of the changes in spasticity after 24 months
Tidsramme: Initial visit (Day 0) to 24 months
|
Initial visit (Day 0) to 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Dr. Jose A. Brizuela, Fundación Rosarina de Neurorehabilitación. Rosario, Argentina.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EMR200077-507
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sklerose, recidiverende remittering
-
BiocadRekrutteringRelapsing-remitting multipel sklerose (RRMS)Rusland
-
Centre Hospitalier Universitaire de NīmesRekrutteringMultipel sklerose (MS) - Relapsing-remittingFrankrig
-
Sichuan Academy of Medical SciencesBeijing Tiantan Hospital; Shandong Provincial Hospital; Tang-Du Hospital; First... og andre samarbejdspartnereIkke rekrutterer endnuMultipel sklerose (MS) Relapsing Remitting
-
Medipol UniversityRekrutteringMultipel sklerose (MS) - Relapsing-remittingTyrkiet (Türkiye)
-
Yeditepe UniversityThe Scientific and Technological Research Council of TurkeyAfsluttetMultipel sclerose | Multipel sklerose (MS) - Relapsing-remittingTyrkiet (Türkiye)
-
Northwestern UniversityTG Therapeutics, Inc.RekrutteringMultipel sclerose | Multipel sklerose (MS) - Relapsing-remittingForenede Stater
-
Cabaletta BioIkke rekrutterer endnuProgressiv multipel sklerose | Multipel sclerose | Multipel sklerose (tilbagefaldende overførelse) | Relapserende multipel sklerose (RMS) | Progressiv multipel sklerose (PMS) | Multipel sklerose (MS) - Relapsing-remitting | Multipel sklerose - Relapsing Remitting
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceAfsluttetMultipel sklerose (MS) - Relapsing-remittingForenede Stater
-
University of AarhusRekrutteringMultipel sklerose (MS) - Relapsing-remittingDanmark
-
German University in CairoAfsluttetMultipel sklerose (MS) - Relapsing-remittingEgypten